Anti-inflammatory supplement produced by ExirNano Sina, selected as the third superior production

0 Feb 01 2016 In بین‌المللی توسط International

Presenting "SinaKorkomin", the knowledge-based enterprise "ExirNano Sina", one of the Pardis Technology Park members, could achieve the joint third place with another enterprise, at the 8th nanotechnology festival at chosen products section. This enterprise presented its nanotechnology based medicine at the nanotechnology festival.

According to the public relations department of Pardis Technology Park, Dr. Mahnaz Ghomi, PhD of analytical chemistry and member of the scientific board of the Islamic Azad University, Science and Research branch, and the CEO of the enterprise ExirNano Sina said: "This company was established in 2009 by Dr. Mahmoudreza Ja’fari, member of scientific board of the pharmacy school of Ferdowsi University of Mashhad, and nanotechnology initiative council patronage.”

The first medicine formulated by the company’s scholars in technical science is liposomal form of the "Doxorubicin HCl” injection cancer medication, its trade name is "SinaDoxosom”, and after obtaining the license, it was produced by Sobhan Oncology Company.

Most researches of this company are about formulation based on micelles, liposomes and nanoparticles based on lipids and its industrial production with injection, oral and topical usage. Being more effective and less toxic, the pharmacokinetics is optimized by applying this method.

By applying new methods, "Exir Nano Sina”is trying to increase medicines advantages for patients. This company is also working to improve the quality of patients’ life by utilizing advanced methods. This company has released two types of medicines by now. The medication "SinaDoxosom” is helpful in four types of cancer and "Sina Curcumin” is based on the active ingredient of turmeric. It also produced another product named "SinaAmfolish” which is effective in curing cutaneous leishmaniasis that will be released until the end of the year.

Edited On : -/-

No Comments.

Reply